THE JABS ARE SUPERFLUOUS.
There was never any need for an emergency v_ccine. There was always only the need to follow the MONOTTI PROTOCOL until at least all the clinical safety trials complete in 2023, if not longer.
https://nulluslocussinegenio.com/2021/03/23/the-monotti-protocol/

THE ANECDOTAL "VACCINE" SHEDDING THREAD. PLEASE post below any personal experiences you had of shedding effects after contact with jabbed individuals. ⬇️

ROBIN,
I completely agree. Those who wish, for medical reasons, to get vaccinated, I’m in no position to tell you not to, but be informed.
But those considering getting vaccinated for non medical reasons....please DON’T!!!
Every person who makes that choice inadvertently coerces those who don’t want this.
A vaxpass system needs a majority of the adults on it to start running, and then it’ll just steamroller everyone else.
And this warning is for everyone: STAY COMPLETELY AWAY FROM THE TOP-UP / VARIANT/ BOOSTER VACCINES.
There’s simply NO JUSTIFICATION for them.
I’ve no idea what is in those vials. No variant is different enough from the original virus to require a different vaccine.
Please DYOR, and don’t hold back from questioning everything.
Thanks!
Mike

Please support the care workers to prevent them from being forced into vaccination for their jobs:
https://www.gov.uk/government/consultations/making-vaccination-a-condition-of-deployment-in-older-adult-care-homes

NATURAL IMMUNITY IS LONG LIVED PROVIDED YOU DON'T RUIN IT WITH A JAB.

"These results suggest that following a typical case of mild COVID-19, SARS-CoV-2-specific CD8+ T cells not only persist but continuously differentiate in a coordinated fashion well into convalescence, into a state characteristic of long-lived, self-renewing memory."

https://www.biorxiv.org/content/10.1101/2021.04.28.441880v1?s=09

A message from a reader on twitter:

"Hi Robin- I’m a big fan of yours. Thanks for all you do. I currently live in Germany and a dentist friend of mine got his AstraZeneca in February / March and was due for his second on Monday. Due to his job, he tests covid everyday at work and is now positive. He doesn’t have any symptoms but had to report it to the health department and quarantine. Upon receiving his call, he expressed annoyance that he can’t get his second jab on Monday and she said oh not to worry. In the Fall, you’ll need the new booster for the Indian Mutation anyway so just wait until that one. He was outraged having never heard about needed boosters for various mutations etc. just FYI what’s going on in Germany amongst other dubious things 😬"

https://fullfact.org/online/yeadon-covid-vaccine/

I’m delighted to see that those fine researchers at FullFact (presumably mustering many PhDs and science degrees between them?) are still busy wasting electrons in their attempts to smear me.
The reason I’m delighted is that counter intelligence doesn’t bother wasting effort on those who represent no threat whatsoever to their false narrative.
This cheers me up no end. Thanks, FullFact! If at any time I start to flag & think I’m not reaching enough people to have even the slightest chance of influencing anything, I run a search. Finding their earnest lies like this tells me they don’t like me expressing an independent opinion.
I’ve news for them: I’ve no intention of stopping. I’ve said it before & I repeat: they’ll need to arrest or vanish me to shut me up. It’s not bravery. There’s no safe, quiet stance available to me, knowing what I do.
These criminals need calling out. If I stop, it’ll make it easier for them to coerce people onto a vaccine passport system.
Don’t let them coerce you. SPEAK OUT while you’ve a chance to.
Best wishes
Mike

We showed that patients (n = 23) who recovered from SARS (the disease associated with SARS-CoV infection) possess long-lasting memory T cells that are reactive to the N protein of SARS-CoV 17 years after the outbreak of SARS in 2003; these T cells displayed robust cross-reactivity to the N protein of SARS-CoV-2.

"Here we studied T cell responses against the structural (nucleocapsid (N) protein) and non-structural (NSP7 and NSP13 of ORF1) regions of SARS-CoV-2 in individuals convalescing from coronavirus disease 2019 (COVID-19) (n = 36). In all of these individuals, we found CD4 and CD8 T cells that recognized multiple regions of the N protein. Next, we showed that patients (n = 23) who recovered from SARS (the disease associated with SARS-CoV infection) possess long-lasting memory T cells that are reactive to the N protein of SARS-CoV 17 years after the outbreak of SARS in 2003; these T cells displayed robust cross-reactivity to the N protein of SARS-CoV-2. We also detected SARS-CoV-2-specific T cells in individuals with no history of SARS, COVID-19 or contact with individuals who had SARS and/or COVID-19 (n = 37). SARS-CoV-2-specific T cells in uninfected donors exhibited a different pattern of immunodominance, and frequently targeted NSP7 and NSP13 as well as the N protein. Epitope characterization of NSP7-specific T cells showed the recognition of protein fragments that are conserved among animal betacoronaviruses but have low homology to ‘common cold’ human-associated coronaviruses. Thus, infection with betacoronaviruses induces multi-specific and long-lasting T cell immunity against the structural N protein."

https://www.nature.com/articles/s41586-020-2550-z?s=09

" Antibodies can only latch onto and help destroy pathogens outside cells and may also occasionally, paradoxically, enhance a pathogen’s ability to infect cell instead by antibody dependent ”enhancement” or ADE. It is only the T-cell that can cleverly sense and destroy pathogens inside infected cells using “sensors” which detect foreign protein fragments ." Eshani King
https://www.bmj.com/content/370/bmj.m3563/rr-6

18-49 years old. Compare to flu jabs.

"In humans with COVID-19 pneumonia, C5b-9, C4d, and mannan-binding lectin serine protease 2 are found in the microvasculature of the lung, and COVID-19–associated skin lesions exhibit colocalization of SARS-CoV-2 spike proteins with C4d and C5b-9 in the cutaneous microvasculature.24  A prospective cohort study of 150 patients with COVID-19 acute respiratory distress syndrome found a high incidence of pulmonary emboli (17%) despite prophylactic anticoagulation.25  Here, we show that the SARS-CoV-2 spike protein subunits, but not N protein or spike protein from a more benign human CoV (OC43), are potent activators of the alternative pathway of complement (APC), and that C5 and factor D inhibitors prevent complement-mediated damage."
https://ashpublications.org/blood/article/136/18/2080/463611/Direct-activation-of-the-alternative-complement

"Dangerous side effects of genetically induced production
of SARS CoV-2 spike proteins
Wolfgang Wodarg 15.3.2021
 
Neither Coronaviruses nor their spikes do enter blood in uncomplicated infections. In more than 90% of all corona-infections immune barriers in the upper respiratory tract or local mucosa immunity will prevent this. This is the result of T-cell driven cross-immunity. (1)
We do not find such an immunity by analyzing antibodies, instead we would have to analyze many T- cell epitopes of corona viruses (2), which is an effort to big to be used for preventive public health reasons.
No matter, which new mutation of a virus will come, the cellular memory of the local immune system is able to recognize tens of different typical epitopes of each respiratory virus species, even then, when some of them have changed by mutations (2).
This seems to be true for all mild respiratory infections and not just for coronaviruses*.
In rare cases of insufficient local immunity, or by medical manipulations (intubation!) viruses happen to enter the blood and become targets of a stronger and more generalized immune defence with humoral and cellular traces (e.g. antibodies) and symptoms like fever or even hampered organ function (less than 1%) (3).
If coronaviruses reach blood, the effect of corona-Spikes within the blood system is well known to be the reason for complicated or deadly Corona infection courses. Some of them are seen as a direct effect in reaction with certain cell receptors, others are reported as secondary effects, happening when infected cells start reproducing new viruses.
 
All those reactions take place or start within some days or in the first weeks after the infection. Those effects may be the reason for the fact that even some younger patients are dying each year with atypical pneumonia, heart or central nervous complications after some infection with different flu viruses like Influenza A or B, Parainfluenza, human Metapneumovirus, RS-Virus, Coronavirus and many others.
 
It is well known that also virus-virus synergism as well as superinfections with bacteria or nosocomial infections may play an important role in those rare complications among children and younger adults. Very often there are other pathogenetic factors that lead to complications. All those cases have to be distinguished from elderly victims, where frailty und chronic diseases weaken the resistance against any additional infectious stress.
 
No matter, where those corona-spikes come from, whether they are part of whole viruses or just spike-proteins, produced by genetically programmed cells, in both cases dangerous reactions may result,  if they reach the patient’s blood vessels.
Again, a normal acute respiratory infection without fever or severer symptoms (> 99%) does not come along with corona-spike protein reaching the blood and does not initiate risky generalized immune alarms.
However when genetically engineered vectors or particles are injected into the upper arm muscle, natural immune barriers or systems of defence are bypassed.
There are not enough competent immune cells in the tissue of the m. deltoideus. And as soon as some closer cells in the muscle start to produce and present spike protein, there should be a strong and more and more generalizing local immune reaction with swellings and pain. This fits well with observed side effects of the ongoing experimental use of all genetically modifying injections.
It is unknown where the new self-made spike proteins remain, or whether parts of them could go with the blood. As there are many blood vessels in the muscle, it may happen often and easily, that part of the injected dose reaches the blood already during injection.
If this happens, the complications may be similar to those, coming along with hematogenous sowing during a complicated infection.
 
In such cases there are three possible risks of vaccination, that can have similar serious consequences and even may happen in combination with each other:
 

https://www.wodarg.com/english/

"The spike-based vaccine conferred acute protection in the brain only if combined with the nucleocapsid-based vaccine.”
https://www.biorxiv.org/content/10.1101/2021.04.26.440920v1

"We found that SARS survivors all have significant levels of antibodies remaining in their blood 17 years after infection. Anti-N antibodies waned more than anti-RBD antibodies, and the latter is known to play a more important role."
https://pubmed.ncbi.nlm.nih.gov/32529906/

"SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity"
https://academic.oup.com/jmcb/article/12/12/916/6028992?s=09

"Our laboratory only tested the effects of the SARS-CoV-2 spike protein in lung vascular cells and those implicated in the development of Pulmonary Arterial Hypertension. However, this protein may also affect the cells of systemic and coronary vasculatures, eliciting other cardiovascular diseases such as coronary artery disease, systemic hypertension, and stroke. In addition to cardiovascular cells, other cells that express ACE2 have the potential to be affected by the SARS-CoV-2 spike protein, which may cause adverse pathological events. Thus, it is important to consider the possibility that the SARS-CoV-2 spike protein produced by the new COVID-19 vaccines triggers cell signaling events that promote PAH, other cardiovascular complications, and/or complications in other tissues/organs in certain individuals"

Vaccines | Free Full-Text | SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines | HTML
https://www.mdpi.com/2076-393X/9/1/36/htm

"N protein is very similar between different coronaviruses – much more so than the spike protein. This means it’s possible that a protective immune response against SARS-CoV-2 N protein could also offer some protection against other related coronaviruses, such as Mers.
Another potential benefit that may arise from including N protein in SARS-CoV-2 vaccines is due to the low mutation rates seen in the N protein sequence. Some changes to the sequence of SARS-CoV-2 have been reported over the course of this pandemic, with the most significant changes occurring in the spike protein. There is some concern that if the spike sequence alters too much, then new vaccines will be required. This could be similar to the current need for annual updating of influenza vaccines. However, as the N protein sequence is much more stable than the spike, vaccines that include a component targeting the N protein are likely to be effective for longer."
https://theconversation.com/covid-vaccines-focus-on-the-spike-protein-but-heres-another-target-150315

"The SARS-CoV-2 virus is more complicated than just a spike protein. There are, in fact, four different proteins that form the overall structure of the virus particle: spike, envelope (E), membrane (M) and nucleocapsid (N). In a natural infection, our immune system recognises all of these proteins to varying degrees. So how important are immune responses to these different proteins, and does it matter that the first vaccines will not replicate these?
Following SARS-CoV-2 infection, researchers have discovered that we actually make the most antibodies to the N protein – not the spike protein. This is the same for many different viruses that also have N proteins. But how N protein antibodies protect us from infection has been a long-standing mystery. This is because N protein is only found inside the virus particle, wrapped around the RNA. Therefore, N protein antibodies cannot block virus entry, will not be measured in neutralisation assays that test for this in the lab, and so have largely been overlooked."

2015: "To examine the emergence potential (the potential to infect humans) of circulating bat CoVs, we built a chimeric virus encoding a novel, zoonotic CoV spike protein -from the RsSHC014-CoV sequence that was isolated from Chinese horseshoe bats"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797993/#__ffn_sectitle

2020: "India pulls up US CDC agency for doing unauthorized Nipah virus research"
https://theeasternlink.com/india-pulls-up-us-agency-for-doing-unauthorized-nipah-virus-research/

India: Whistleblower actor arrested for "vaccine misinformation". High court sets bail.
https://m.timesofindia.com/city/chennai/madras-high-court-orders-actor-mansoor-ali-khan-to-pay-rs-2-lakh-for-covid-19-vaccine-procurement/articleshow/82305786.cms